Aatke van der Maas

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

Noortje van Herwaarden, Aatke van der Maas, M.J.M. Minten et al. · BMJ · 2015 · 181 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +17

Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study

Aatke van der Maas, Elisabeth Lie, Robin Christensen et al. · Annals of the Rheumatic Diseases · 2012 · 135 citations

Medicine, Clinical Sciences, Internal Medicine +17

Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study

Aatke van der Maas, Wietske Kievit, Bart J. F. van den Bemt et al. · Annals of the Rheumatic Diseases · 2012 · 102 citations

Medicine, Clinical Sciences, Pharmacotherapy +16

Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial

Diane Marsman, Nathan den Broeder, F.H.J. van den Hoogen et al. · The Lancet Rheumatology · 2021 · 53 citations

Medicine, Clinical Sciences, Internal Medicine +5

Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial

Chantal A M Bouman, Noortje van Herwaarden, F.H.J. van den Hoogen et al. · Annals of the Rheumatic Diseases · 2017 · 51 citations

Medicine, Internal Medicine, Pharmacotherapy +16